Back to Agenda
Session 6 Track 2: Structured Content Management
Session Chair(s)
Michiel Stam
Director Regulatory Information Management
Qdossier - A Celegence Company, United Kingdom
Maintaining information on product characteristics for marketed and development drugs across all countries is a complex and laborious task. Content is often duplicated, difficult to retrieve and reviewed and approved multiple times, resulting in a waste of time and resources. Managing this contents and associated processes in a structured way offers many great advantages, including increased efficiency, transparency, improved quality of information, and better decision making. This session will focus on several business cases for structured contents management and the importance of standardized or structured processes, utilizing structured data.
Learning Objective : Participants should be able to: Express the importance of standardized or structured processes within their department and across the organization. Organize a cross-department meeting to discuss the value of structured processes and structured data. Create a structured process, utilizing structured data, for a repetitive activity within their department. Identify the key process milestones.
Speaker(s)
Structured Information and Process Management Reduce Drug Development by $250 Million
Jack Yeager
Sylogent, United States
CEO
DOCX; Ability to Channel Regulatory Information from Company Databases Through Documents to Agency Databases
Hans van Bruggen, MSc
Qdossier, a Celegence Company, Netherlands
CSO
A Grand Design
Mark Cottingham
F. Hoffmann-La Roche Ltd, Switzerland
Sr. Business Lead in Operational Business Excellence Group of Pharma Technical
Have an account?